2024
Association of Chronic Kidney Disease and Kidney Failure with Replacement Therapy with Procedural and Long-Term Outcomes after First Generation Watchman Device: Insights from the NCDR LAAO Registry
Munir M, Tan Z, Pun P, Wang Y, Tandar A, Darden D, Hsu J, Friedman D, Curtis J, Freeman J. Association of Chronic Kidney Disease and Kidney Failure with Replacement Therapy with Procedural and Long-Term Outcomes after First Generation Watchman Device: Insights from the NCDR LAAO Registry. Heart Rhythm 2024 PMID: 39515495, DOI: 10.1016/j.hrthm.2024.10.071.Peer-Reviewed Original ResearchChronic kidney diseaseLong-term outcomesLeft atrial appendage occlusionAssociation of chronic kidney diseaseNational Cardiovascular Data Registry LAAO RegistryReplacement therapyAdverse eventsAtrial fibrillationKidney diseaseKidney failureAssociated with higher ratesIn-hospital deathRisk of strokeRate of strokeBilling claimsAF patientsProcedural complicationsAppendage occlusionWatchman deviceMultivariate analysisKFRTHigh riskPatientsRegistryComplications
2023
SCAI/HRS Expert Consensus Statement on Transcatheter Left Atrial Appendage Closure
Saw J, Holmes D, Cavalcante J, Freeman J, Goldsweig A, Kavinsky C, Moussa I, Munger T, Price M, Reisman M, Sherwood M, Turi Z, Wang D, Whisenant B. SCAI/HRS Expert Consensus Statement on Transcatheter Left Atrial Appendage Closure. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 100577. PMID: 39130704, PMCID: PMC11307869, DOI: 10.1016/j.jscai.2022.100577.Peer-Reviewed Original ResearchAtrial appendage closureAppendage closureConsensus statementTranscatheter Left Atrial Appendage ClosureLeft atrial appendage closureImportant clinical trialsExpert consensus statementLeft atrial appendageCardiovascular Computed TomographyDrug Administration approvalEvidence-based best practicesThromboembolic riskWatchman deviceLAAC procedureAtrial fibrillationAtrial appendageAdministration approvalClinical trialsCardiovascular AngiographyAmerican CollegeComputed tomographyClinical developmentClinical practiceEndovascular devices
2022
Device-Sizing and Associated Complications With Left Atrial Appendage Occlusion: Findings From the NCDR LAAO Registry
Sandhu A, Varosy P, Du C, Aleong R, Tumolo A, West J, Tzou W, Curtis J, Freeman J, Friedman D, Hess P. Device-Sizing and Associated Complications With Left Atrial Appendage Occlusion: Findings From the NCDR LAAO Registry. Circulation Cardiovascular Interventions 2022, 15: e012183. PMID: 36472194, DOI: 10.1161/circinterventions.122.012183.Peer-Reviewed Original ResearchConceptsAtrial appendage occlusionAppendage occlusionPericardial effusionLower oddsOversized deviceComposite adverse outcomeNonvalvular atrial fibrillationShort-term complicationsShort-term outcomesSignificant leakDevice embolismSelect patientsAdverse eventsWatchman deviceAssociated complicationsPeridevice leakAtrial fibrillationAdverse outcomesDevice embolizationHigh prevalenceDevice migrationManufacturer's recommendationsPatientsStudy periodUndersized devicesLeft Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis.
Chew DS, Zhou K, Pokorney SD, Matchar DB, Vemulapalli S, Allen LA, Jackson KP, Samad Z, Patel MR, Freeman JV, Piccini JP. Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis. Annals Of Internal Medicine 2022, 175: 1230-1239. PMID: 35969865, DOI: 10.7326/m21-4653.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsHigh bleeding riskLower stroke riskClinical effectiveness dataAtrial fibrillationBleeding riskStroke riskOral anticoagulantsIschemic strokeEffectiveness dataHAS-BLED scoreIndividual riskHigh stroke riskMajor bleeding riskNonvalvular atrial fibrillationPatient's individual riskPrimary end pointAtrial appendage occlusionBase-case analysisOral anticoagulationPrior strokeVASc scoreStroke preventionWatchman deviceAppendage occlusionAntithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation
Freeman JV, Higgins AY, Wang Y, Du C, Friedman DJ, Daimee UA, Minges KE, Pereira L, Goldsweig AM, Price MJ, Reddy VY, Gibson D, Doshi SK, Varosy PD, Masoudi FA, Curtis JP. Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation. Journal Of The American College Of Cardiology 2022, 79: 1785-1798. PMID: 35512858, PMCID: PMC9097170, DOI: 10.1016/j.jacc.2022.02.047.Peer-Reviewed Original ResearchConceptsLeft atrial appendage occlusionAdverse eventsPivotal trialsWatchman deviceTreatment protocolAntithrombotic strategiesAppendage occlusionLower riskFrailty regressionPercutaneous left atrial appendage occlusionNational Cardiovascular Data RegistryContemporary U.S. practiceDual antiplatelet therapyAtrial appendage occlusionConcomitant aspirinPostprocedure careAdjusted riskAntiplatelet therapyAntithrombotic medicationAntithrombotic therapyAtrial fibrillationAdverse outcomesTrial protocolAntithrombotic agentsMedication strategiesChanges in left atrial appendage orifice following percutaneous left atrial appendage closure using three-dimensional echocardiography
Ortiz-Leon XA, Posada-Martinez EL, Bregasi A, Chen W, Crandall I, Pereira J, Faridi KF, Akar JG, Lin BA, McNamara RL, Freeman JV, Curtis J, Arias-Godinez JA, Sugeng L. Changes in left atrial appendage orifice following percutaneous left atrial appendage closure using three-dimensional echocardiography. The International Journal Of Cardiovascular Imaging 2022, 38: 1361-1369. PMID: 35064846, DOI: 10.1007/s10554-022-02525-y.Peer-Reviewed Original ResearchLAA occlusionWatchman deviceLAA orificeD velocityPercutaneous left atrial appendage closureLeft atrial appendage closureEccentricity indexLAA orifice diameterAtrial appendage closureAtrial appendage occlusionPercutaneous LAA occlusionPeak SMaximum diameterAtrial appendage orificeShort-axis viewThree-dimensional echocardiographyLong-term contraindicationsAppendage closureAppendage occlusionAtrial fibrillationTransesophageal echocardiography imagesAxis viewPatientsOcclusionSignificant differences
2016
Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL
Freeman JV, Hutton DW, Barnes GD, Zhu RP, Owens DK, Garber AM, Go AS, Hlatky MA, Heidenreich PA, Wang PJ, Al-Ahmad A, Turakhia MP. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circulation Arrhythmia And Electrophysiology 2016, 9: e003407. PMID: 27307517, PMCID: PMC4911813, DOI: 10.1161/circep.115.003407.Peer-Reviewed Original ResearchConceptsLAA closureLeft atrial appendageQuality-adjusted life yearsPROTECT AFAtrial fibrillationPercutaneous closureWatchman deviceAtrial appendageLife yearsTrial dataWATCHMAN LAA closure devicePROTECT AF trialIncremental cost-effectiveness ratioMajor adverse eventsPrevention of strokeAtrial appendage closureProspective Randomized EvaluationLAA closure deviceLong-term trial resultsQuality-adjusted survivalCost-effectiveness ratioCost-effectiveness resultsMedical anticoagulationAF trialAdverse events